ASZ1 Stock Overview A pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Alimera Sciences, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Alimera Sciences Historical stock prices Current Share Price €4.73 52 Week High €5.09 52 Week Low €2.43 Beta 0.27 1 Month Change 0.85% 3 Month Change -6.44% 1 Year Change 68.75% 3 Year Change 27.02% 5 Year Change -23.26% Change since IPO -95.96%
Recent News & Updates
Alimera Sciences Files Form 15 Sep 28
New major risk - Financial position Sep 19 ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) completed the acquisition of Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.
Second quarter 2024 earnings released: US$0.061 loss per share (vs US$1.32 loss in 2Q 2023) Aug 07 ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) signed a definitive agreement to acquire Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others for approximately $300 million. Jun 25
First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.71 loss in 1Q 2023) May 16 See more updates
Alimera Sciences Files Form 15 Sep 28
New major risk - Financial position Sep 19 ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) completed the acquisition of Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.
Second quarter 2024 earnings released: US$0.061 loss per share (vs US$1.32 loss in 2Q 2023) Aug 07 ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) signed a definitive agreement to acquire Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others for approximately $300 million. Jun 25
First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.71 loss in 1Q 2023) May 16
New major risk - Revenue and earnings growth May 15
Alimera Sciences, Inc. to Report Q1, 2024 Results on May 14, 2024 May 01
Forecast breakeven date pushed back to 2025 Apr 24
Alimera Sciences, Inc. Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network Mar 20
Forecast breakeven date pushed back to 2026 Mar 09
New major risk - Revenue and earnings growth Mar 08
Alimera Sciences, Inc. Provides Revenue Guidance for the Year 2024 Mar 08
Alimera Sciences, Inc. Provides Revenue Guidance for the Year 2024 Mar 07
Alimera Sciences, Inc. to Report Q4, 2023 Results on Mar 07, 2024 Mar 01
Alimera Sciences, Inc. Names Elliot Maltz as Chief Financial Officer Jan 02
Alimera Sciences, Inc. Appoints Todd Wood as President of U.S. Operations Dec 13
Alimera Sciences, Inc Appoints Maggie A. Pax to its Board of Directors Nov 09
Alimera Announces Scientific Data Highlighting ILUVIEN to Be Presented at the American Academy of Ophthalmology Nov 01
Third quarter 2023 earnings released: US$0.06 loss per share (vs US$0.75 loss in 3Q 2022) Oct 27
Alimera Sciences, Inc. to Report Q3, 2023 Results on Oct 26, 2023 Oct 17
Alimera Sciences, Inc. Announces Management Appointments Oct 05
New major risk - Shareholder dilution Aug 17
New major risk - Financial position Aug 14
Second quarter 2023 earnings released: US$1.32 loss per share (vs US$0.45 loss in 2Q 2022) Aug 11
Alimera Sciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023 Aug 03
Alimera Sciences, Inc., Annual General Meeting, Aug 01, 2023 Jun 30
Forecast breakeven date moved forward to 2024 May 21 Alimera Sciences, Inc. entered into an agreement to acquire YUTIQ® from EyePoint Pharmaceuticals, Inc. for $82.5 million.
First quarter 2023 earnings released: US$0.71 loss per share (vs US$0.85 loss in 1Q 2022) May 16
Alimera Sciences, Inc. to Report Q1, 2023 Results on May 15, 2023 May 09
Less than half of directors are independent May 08
Forecast breakeven date pushed back to 2025 Apr 03
Full year 2022 earnings released: US$2.59 loss per share (vs US$0.66 loss in FY 2021) Apr 02 Alimera Sciences, Inc. Appoints Russell L. Skibsted as Senior Vice President
Alimera Sciences, Inc. Announces Abstracts Regarding Consensus Among US Retina Specialists and Reduced Retinal Thickness Variability Leading to Improved Visual Outcomes Following ILUVIEN®Administration Nov 30
Third quarter 2022 earnings released: US$0.75 loss per share (vs US$0.60 loss in 3Q 2021) Nov 16
Insufficient new directors Nov 16
Alimera Sciences, Inc. Announces Resignation of J. Philip Jones as CFO, Effective from November 28, 2022 Nov 05
Alimera Sciences, Inc. to Report Q3, 2022 Results on Nov 14, 2022 Nov 03
Alimera Sciences, Inc. Announces Paladin Phase 4 Study Confirms ILUVIEN Patients' Reduced Need for Multiple Treatments Oct 07
Alimera Sciences, Inc. Announces Multiple Abstracts Highlighting ILUVIEN® Real World Data at EURETINA Annual Congress Sep 01
Insufficient new directors Aug 02
Second quarter 2022 earnings released: US$0.45 loss per share (vs US$1.04 profit in 2Q 2021) Jul 28
Alimera Sciences, Inc. Announces That the Paladin Phase 4 Study Confirms the Safety of Iluvien® (Fluocinolone Acetonide Intravitreal Implant) 0.19 Mg Sustained Release Intravitreal Implant and Provides A Durable Treatment Option That Reduces the Frequency of Recurrence for Patients with Diabetic Macular Edema Jul 27
Alimera Sciences, Inc. to Report Q2, 2022 Results on Jul 27, 2022 Jul 23
Alimera Sciences, Inc., Annual General Meeting, Jul 12, 2022 Jun 02
Alimera Sciences, Inc. Announces that Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to ILUVIEN Use for IOP Outcomes May 13
First quarter 2022 earnings released: US$0.85 loss per share (vs US$0.63 loss in 1Q 2021) May 10
Alimera Sciences, Inc. to Report Q1, 2022 Results on May 09, 2022 May 07
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 26
Alimera Sciences, Inc. to Report Q4, 2021 Results on Feb 24, 2022 Feb 18
President recently bought €108k worth of stock Nov 05
Investor sentiment improved over the past week Oct 18
Investor sentiment improved over the past week Oct 18
Alimera Sciences Announces National Pricing and Reimbursement Granted for ILUVIEN for DME in Belgium Aug 25
Investor sentiment deteriorated over the past week Aug 20
Second quarter 2021 earnings released: EPS US$1.03 (vs US$0.51 loss in 2Q 2020) Aug 14
Independent Director Mary Szela has left the company Jun 19
First quarter 2021 earnings released: US$0.63 loss per share (vs US$0.24 loss in 1Q 2020) May 01
Alimera Sciences, Inc. announced that it has received $10 million in funding from Ocumension Therapeutics Apr 16
Full year 2020 earnings released: US$1.04 loss per share (vs US$2.19 loss in FY 2019) Mar 02
Revenue beats expectations Mar 02
New 90-day high: €7.60 Feb 19
Alimera Sciences, Inc. to Report Q4, 2020 Results on Feb 24, 2021 Feb 18
New 90-day high: €4.60 Jan 08
New 90-day low: €3.38 Nov 02
Third-quarter earnings released: Revenue beats expectations Oct 30
Third quarter earnings released Oct 30
New 90-day low: €3.90 Oct 13
New 90-day low: €4.56 Sep 19
Alimera Sciences, Inc. to Report Q2, 2020 Results on Jul 29, 2020 Jul 23 Shareholder Returns ASZ1 DE Pharmaceuticals DE Market 7D 0% -2.4% -0.7% 1Y 68.8% -16.3% 10.1%
See full shareholder returns
Return vs Market: ASZ1 exceeded the German Market which returned 6.8% over the past year.
Price Volatility Is ASZ1's price volatile compared to industry and market? ASZ1 volatility ASZ1 Average Weekly Movement 24.6% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: ASZ1's share price has been volatile over the past 3 months.
Volatility Over Time: ASZ1's weekly volatility has increased from 13% to 25% over the past year.
About the Company Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).
Show more Alimera Sciences, Inc. Fundamentals Summary How do Alimera Sciences's earnings and revenue compare to its market cap? ASZ1 fundamental statistics Market cap €256.97m Earnings (TTM ) -€13.68m Revenue (TTM ) €89.29m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ASZ1 income statement (TTM ) Revenue US$99.68m Cost of Revenue US$13.57m Gross Profit US$86.11m Other Expenses US$101.39m Earnings -US$15.27m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.28 Gross Margin 86.39% Net Profit Margin -15.32% Debt/Equity Ratio 179.8%
How did ASZ1 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/09/23 11:45 End of Day Share Price 2024/09/19 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Alimera Sciences, Inc. is covered by 14 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Molloy Alliance Global Partners Andrew D'Silva B. Riley Securities, Inc. Caroline Corner Cantor Fitzgerald & Co.
Show 11 more analysts 
